- Cholesterol dysmetabolism in motor neurons is a central ALS pathogenic axis; oxysterols induce lysosomal and mitochondrial dysfunction causing oxiapoptophagy.
- TDP-43 dysfunction and ALS gene variants impair MAMs and cholesterol trafficking; GWAS and MR link higher LDL, total cholesterol, ApoB to increased ALS risk.
- iPSC-LMN screening identified ropinirole suppressing cholesterol biosynthesis, reducing ROS and TDP-43/FUS aggregation, improving mitochondria; PRS integration may stratify patients for cholesterol-targeted therapy.
Rinsho Shinkeigaku. 2026 Nov 14. doi: 10.5692/clinicalneurol.cn-002264. Online ahead of print.
ABSTRACT
In amyotrophic lateral sclerosis (ALS), cholesterol dysmetabolism in motor neurons has emerged as a central pathogenic axis. Oxysterols generated under oxidative stress exert potent lower motor neuron toxicity via lysosomal and mitochondrial dysfunction and by triggering oxiapoptophagy, a form of cell death in which oxidative stress, apoptosis, and autophagy co-occur. Moreover, TAR DNA-binding protein 43 (TDP-43) dysfunction and pathogenic variants in ALS-related genes including C9orf72, VAPB, and SIGMAR1 can amplify lipid toxicity through impaired function of mitochondria-associated endoplasmic reticulum membranes (MAMs) and defective intracellular cholesterol trafficking. Genome-wide association studies (GWAS) and Mendelian randomization (MR) analyses indicate that genetically predicted elevations in low-density lipoprotein cholesterol (LDL-C), total cholesterol, and apolipoprotein B (ApoB) are associated with increased ALS risk, whereas the effects of statins appear heterogeneous and context-dependent, varying by agent, dose, and treatment duration. In drug discovery using patient-derived induced pluripotent stem cell (iPSC)-derived lower motor neurons (iPSC-LMNs), ropinirole hydrochloride suppresses the expression of enzymes involved in de novo cholesterol synthesis while reducing reactive oxygen species, inhibiting aggregation of TDP-43 and fused in sarcoma (FUS), and improving mitochondrial function; importantly, in vitro responsiveness correlates with clinical efficacy. Furthermore, integrating a polygenic risk score (PRS) for total cholesterol with iPSC-LMN phenotypes has been proposed as a stratification strategy to define an ALS subtype driven by hyperactive cholesterol metabolism and to identify patients more likely to benefit from cholesterol biosynthesis-suppressing therapies. Collectively, candidate disease-modifying interventions targeting cholesterol dysmetabolism are increasingly positioned as a promising translational research axis in ALS.
PMID:43035909 | DOI:10.5692/clinicalneurol.cn-002264
Share Evidence Blueprint
Save to Google Notes

Search Google Scholar
⭐ My Revision List

